
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly and Co demonstrated robust financial performance in 2Q25, surpassing revenue and earnings expectations while also raising full-year guidance. Notably, sales of Mounjaro outside the U.S. surged by 60% quarter-over-quarter, indicating strong growth potential in international markets alongside anticipated improvements in their obesity treatment options. The positive outlook is further supported by projected sales growth of 20.5% for 2026 and exceptional earnings per share growth of 41%, underscoring the company’s strong position in the pharmaceutical market.
Bears say
Eli Lilly and Co faces several substantial risks that negatively impact its stock outlook, including increasing pricing and rebate pressures, and a disappointing trajectory for its tirzepatide product, Mounjaro, which has failed to demonstrate expected cardiac outcome benefits. Additionally, the forecast for orforglipron has been reduced significantly, reflecting growing competitive threats in the cardiometabolic space and a decline in sales expectations, particularly for Zepbound and Mounjaro in the coming quarters. The cumulative effect of these factors raises concerns about Lilly's overall revenue growth potential moving forward.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares